Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 1-Year Low – Time to Sell?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s share price reached a new 52-week low on Friday . The stock traded as low as $731.80 and last traded at $733.47, with a volume of 31478 shares changing hands. The stock had previously closed at $740.97.

Analyst Ratings Changes

REGN has been the subject of several research reports. Barclays dropped their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Oppenheimer reduced their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Wells Fargo & Company dropped their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 22nd. Finally, Piper Sandler reduced their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $1,099.90.

Regeneron Pharmaceuticals Price Performance

The business has a fifty day moving average of $849.77 and a 200 day moving average of $1,004.02. The firm has a market cap of $80.36 billion, a P/E ratio of 18.10, a PEG ratio of 2.32 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mizuho Securities USA LLC lifted its holdings in Regeneron Pharmaceuticals by 625.5% during the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after purchasing an additional 51,162 shares during the last quarter. Tri Locum Partners LP raised its position in shares of Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after purchasing an additional 8,949 shares during the period. Simplify Asset Management Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 50.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after buying an additional 3,231 shares during the last quarter. Catalytic Wealth RIA LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $1,334,000. Finally, Daiwa Securities Group Inc. grew its stake in Regeneron Pharmaceuticals by 12.3% in the 3rd quarter. Daiwa Securities Group Inc. now owns 20,384 shares of the biopharmaceutical company’s stock valued at $21,428,000 after buying an additional 2,234 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.